Analysts' recommendations: Gamida Cell Ltd.

24-01-29	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
23-11-15	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
23-11-15	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
23-05-19	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
23-05-16	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases: Gamida Cell Ltd.

24-03-27	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
24-03-27	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
24-03-22	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
24-02-23	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
24-01-29	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors: Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	2021-05-31
Rory Nealon COO	Chief Operating Officer	59	2024-05-23

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	2019-03-31

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets 12:54:51 2024-05-24 EDT			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

25-05-26	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
24-07-22	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT

Market Cap	2.62M 2.33M 2.17M 1.98M 3.73M 252M 3.77M 26.28M 10.18M 129M 9.83M 9.62M 413M	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	39.01M 34.66M 32.35M 29.48M 55.61M 3.75B 56.12M 391M 152M 1.92B 146M 143M 6.15B	EV / Sales 2022	-	EV / Sales 2023	51,081,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

25-05-26	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
24-07-22	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
24-06-18	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
24-06-18	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
24-06-18	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
24-06-17	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
24-05-23	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-04-09	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
24-04-04	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
24-03-28	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
24-03-28	Top Premarket Decliners	MT
24-03-27	Top Midday Decliners	MT
24-03-27	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

3 years	0.01	1.05
5 years	0.01	4.72
10 years	0.01	15.41

Gamida Cell Ltd. Stock

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation: Gamida Cell Ltd.

Latest news: Gamida Cell Ltd.

Analysts' recommendations: Gamida Cell Ltd.

Press Releases: Gamida Cell Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/31/24	Ronit Simantov	Free	Chief Technology Officer	480,319	0.3621%
1/31/24	Ivan Borrello	Free	Director	200,000	0.1508%
1/31/24	Kenneth Moch	Free	Director	200,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.25%	2.62M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	+0.04%	-0.16%	+47.37%	+105.86%	39.05B
Weighted average by Cap.	+0.12%	-0.84%	+56.96%	+138.26%

	2022	2023
Net sales	-	1.78 1.59 1.48 1.35 2.54 171.5 2.57 17.9 6.94 87.67 6.7 6.55 281.38
Net income	-79.38M -70.52M -65.82M -60M -113M -7.63B -114M -797M -309M -3.9B -298M -292M -12.52B	-63M -55.97M -52.24M -47.62M -89.8M -6.06B -90.64M -632M -245M -3.1B -237M -231M -9.94B
Net Debt	39.31M 34.93M 32.6M 29.71M 56.03M 3.78B 56.56M 394M 153M 1.93B 148M 144M 6.2B	36.39M 32.33M 30.18M 27.5M 51.87M 3.5B 52.36M 365M 142M 1.79B 137M 134M 5.74B